Abstract 1922P
Background
Advanced angiosarcoma comprises an aggressive sarcoma subset that exhibits poor prognosis and short-term duration of responses. Series treated with anthracyclines or taxanes reported an mPFS that ranged from 2.7 to 3.7 m. A trial with sorafenib reported a mPFS of 1.8 and 3.8 m, 6-m-PFSr of 25% and 31% (9m-PFSr of 0 and 3.8%), ORR of 15 and 13% and mOS of 9 and 12 m, for superficial and visceral cohorts respectively. As IMMUNOSARC I master-trial exploring sunitinib (S) plus nivolumab (N) in sarcoma detected signal of activity in angiosarcoma patients, a specific cohort of vascular sarcomas was designed as phase II trial in IMMUNOSARC II (NCT03277924).
Methods
Advanced, recently progressing, measurable and centrally reviewed vascular sarcomas (angiosarcoma, intimal sarcoma and epithelioid hemangioendothelioma) were enrolled and treated with S: 37.5 mg/d in first 14 days, then continued with 25 mg/d, along with N 240 mg every 2 weeks up to progression or intolerance. Imaging tests were assessed every 8 weeks. The main endpoint was 6m-PFSr, and the statistical assumptions were obtaining a 6m-PFSr in at least 11 patients out of 23 patients, with H0=30% and H1=60% (α 0.05; β 0.10).
Results
Patients with angiosarcoma (17), EHE (6) and intimal sarcomas (3) were accrued from Oct. 2019 to Apr. 2023 in 8 centers from Spain, Italy and UK. Patients had a median age of 60 y (25-82), F=20/M=6 distribution and a median of previous lines of 2 (0-5). Median follow-up was 24 m (5.9-42.1). The 6m-PFSr was 45% (23-66) for 23 evaluable patients. Considering angiosarcoma patients, there were 5 (33%) PR, 7 (47%) SD and 3 (20%) PD out of 15 evaluable patients. The mPFS was 3.93 m and the 6m-PFSr was 36% (11-61). The mOS was 15.73 m (1.83-29.64). End-of-treatment reasons were PD 71%, toxicity 22% and doctor decision 7%. Most common grade 3-4 TREAEs were neutropenia (11.8%) and asthenia (11.8%).
Conclusions
S and N combination has demonstrated to be active in advanced vascular sarcomas. This activity favorably compares with that previously reported for sorafenib activity. Even though the outcome did not reach the H1, antiangiogenics and PD1 inhibitors deserve to be explored, maybe with other combinations, in vascular sarcomas.
Clinical trial identification
NCT03277924.
Editorial acknowledgement
Legal entity responsible for the study
Spanish Group for Research on Sarcoma (GEIS).
Funding
Pfizer and BMS.
Disclosure
J. Martinez Trufero: Financial Interests, Personal, Advisory Board, Advisory Board meeting: PharmaMar, Eisai; Financial Interests, Personal, Invited Speaker: Roche, Eisai, Merck, Medicamenta, MSD, Ipsen; Financial Interests, Personal, Advisory Board, Advisory Board Meeting: GSK, Deciphera, Boehringer Ingelheim, Eisai; Financial Interests, Institutional, Local PI, Clinical trial: RAIN Therapeutics, Blueprint, Lilly, Kariopharm Therapeutics, Syneos Health, Boehringer Ingelheim, Ayala Pharmaceuticals, SynOx Therapeutics; Non-Financial Interests, Member of Board of Directors, Spanish group of Sarcoma Research: GEIS Group; Non-Financial Interests, Member of Board of Directors, Spanish Group of Head and Neck cancer Research: TTCC Group. S. Strauss: Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board, medical advisor: Ceridwen Oncology. S. Stacchiotti: Financial Interests, Personal, Advisory Board: Bayer, Bavarian Nordic, Daiichi Sankyo, Novartis, Ikena, Astex Pharmaceuticals, Rain Therapeutics; Financial Interests, Personal, Invited Speaker: GSK, PharmaMar, Aadi; Financial Interests, Personal, Advisory Board, Advisory board meeting: Agenus; Financial Interests, Personal, Advisory Board, Advisory board meetings: Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker, Lectures: Gentili; Financial Interests, Personal, Advisory Board, Advisory board: Servier; Financial Interests, Institutional, Local PI: Advenchen, Deciphera, Epizyme, Daiichi Sankyo, GSK, Karyopharm, PharmaMar, SpringWorks, Hutchison MediPharma International Inc, Inhibrix; Financial Interests, Institutional, Coordinating PI: Bayer; Financial Interests, Institutional, Funding: Blueprint, Novartis; Non-Financial Interests, Member of Board of Directors, Secretary: Connective Tissue Oncology; Non-Financial Interests, Advisory Role: Chordoma Foundation, Epithelioid Haemangiondothelioma Foundation , Desmoid Foundation , Epithelioid Hemangioendothelioma (EHE) Rare Cancer Charity (UK); Non-Financial Interests, Other, Secretary: EORTC soft tissue and bone sarcoma group; Non-Financial Interests, Leadership Role, President: Italian Sarcoma Group. D. Da Silva Moura: Financial Interests, Personal, Other, Travel: Pfizer. J. Martin-Broto: Financial Interests, Personal, Advisory Board, Honoraria: Lilly, PharmaMar, Eisai, Bayer, Roche, Boehringer Ingelheim, Amgen; Financial Interests, Personal, Invited Speaker: PharmaMar; Financial Interests, Personal, Advisory Board, Speaker: Tecnofarma, Asofarma; Financial Interests, Institutional, Coordinating PI: PharmaMar, Eisai, Novartis, IMMIX Biopharma, Lixte, Karyopharm, Bayer, Celgene, Pfizer, BMS, Lilly; Financial Interests, Institutional, Local PI: Blueprint, Deciphera, Nektar, Forma, Amgen, Daiichi Sankyo, Arog, Adaptimmune, GSK, Ran Therapeutics, Inhibrx, Ayala Pharmaceuticals, Philogen, Cebiotex, PTC Therapeutics, Inc. and SpringWorks therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1840P - RNASEH2B loss and PARP inhibition (parpi) in metastatic castration resistant prostate cancer (mCRPC)
Presenter: Juliet Carmichael
Session: Poster session 15
1841TiP - Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Presenter: Alicia Morgans
Session: Poster session 15
1842TiP - Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
Presenter: Johann de Bono
Session: Poster session 15
1923P - Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma
Presenter: Yoichi Naito
Session: Poster session 15
1924P - Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study
Presenter: Cheng-Ming Sun
Session: Poster session 15
1925P - Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Presenter: Neal Chawla
Session: Poster session 15
1926P - Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
Presenter: Javier Martin-Broto
Session: Poster session 15
1927P - Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Presenter: Axel Le Cesne
Session: Poster session 15
1928P - Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010
Presenter: Jean-Yves Blay
Session: Poster session 15
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15